EcoDrugPlus

Ectonucleotide Pyrophosphatase/phosphodiesterase 2

Ensembl ID : ENSLCRG00005006058
Gene Symbol: ENPP2
3 Cross references
226 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 1

Ensembl ID : ENSLCRG00005023508
Gene Symbol: EGLN1
3 Cross references
220 Possible Orthologues:

Egl-9 Family Hypoxia-Inducible Factor 2

Ensembl ID : ENSLCRG00005015002
Gene Symbol: EGLN2
2 Cross references
191 Possible Orthologues:

Egl-9 Family Hypoxia-Inducible Factor 3

Ensembl ID : ENSLCRG00005010568
Gene Symbol: EGLN3
3 Cross references
197 Possible Orthologues:

Endothelial Pas Domain Protein 1b

Ensembl ID : ENSLCRG00005019258
Gene Symbol: EPAS1B
3 Cross references
212 Possible Orthologues:

Endothelin Converting Enzyme 1

Ensembl ID : ENSLCRG00005023723
Gene Symbol: ECE1
3 Cross references
230 Possible Orthologues:

Endothelin Receptor Type Aa

Ensembl ID : ENSLCRG00005010744
Gene Symbol: EDNRAA
3 Cross references
205 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSLCRG00005013348
Gene Symbol: EDNRB
3 Cross references
195 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSLCRG00005023486
Gene Symbol: EDNRB
3 Cross references
196 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSLCRG00005011286
Gene Symbol: LOC104935544
3 Cross references
197 Possible Orthologues:

Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit

Ensembl ID : ENSLCRG00005014624
Gene Symbol: EZH2
3 Cross references
229 Possible Orthologues:

Ephrin Type-B Receptor 4

Ensembl ID : ENSLCRG00005019756
Gene Symbol: LOC104938675
3 Cross references
168 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).